Four million Americans suffer from glaucoma, an incurable eye disease that slowly degrades peripheral vision and eventually leads to blindness. A new treatment could potentially stop this degradation and possibly save people’s vision before it’s too late.

Raquel Lieberman, a professor in the School of Chemistry and Biochemistry and the Parker H. Petit Institute for Bioengineering and Bioscience, and her lab team have discovered two new antibodies with promise to treat glaucoma. The antibodies can break down the protein myocilin, which, when it malfunctions, can cause glaucoma.

Lieberman’s group recently published this research in the Proceedings of the National Academy of Sciences: Nexus.